Gilead to launch ‘Zydelig Tab’ in the domestic market
Gilead Sciences has acquired a domestic sales approval for Zydelig(generic name: idealisib), a lymphocytic leukemia treatment.
The Ministry of Food and Drug Safety approved sales of Zydelig Tab 100mg and 150mg, a B-cell non-Hodgkin lymphomas treatment.
Zydelig is an anticancer drug which inhibi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
